SAN FRANCISCO — Fremanezumab reduced the use of acute headache medications and effectively prevented chronic migraine among patients with or without medication overuse, according to a presentation at the American Headache Society Annual Scientific Meeting.
Stephen Silberstein, MD, director of the Headache Center at Jefferson University Hospitals, and colleagues conducted a study to assess if fremanezumab (Teva Pharmaceutical Industries) reduces the average of monthly headache days compared with placebo. They also evaluated whether fremanezumab affected medication overuse.
No commercial support for this activity.
Heart in Diabetes
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2018 Healio All Rights Reserved.